XBiotech Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $0.0 | $4.0 | $18.4 |
| Operating income | -$55.7 | -$42.5 | -$37.5 | -$34.5 | -$25.1 |
| Net income | -$45.5 | -$38.5 | -$24.6 | -$32.9 | -$17.4 |
| Cash Flow Statement | |||||
| Free cash flow | -$40.2 | -$32.3 | -$19.1 | -$15.4 | $65.9 |
| Dividends | — | — | — | $0.0 | $75.0 |
| Share repurchases | — | $0.0 | $<0.1 | $0.0 | — |
Shares outstanding 30.5M · Free float 67.4%
Annual filing data through FY ended December 31, 2025; float as of October 13, 2026.
XBiotech Leads Buying Intensity; Gold.com Draws $3.93 Million